The U.S. FDA approved Jazz Pharmaceuticals and Roche’s combination as a first-line maintenance therapy for extensive-stage small-cell lung cancer, based on the phase III Imforte study demonstrating a significant reduction in disease progression and mortality. Separately, the agency approved a new generic version of mifepristone, expanding access to medical abortion. These regulatory decisions mark important milestones for oncology and reproductive health sectors, highlighting ongoing innovation and patient access improvements.